BIOMARIN PHARMACEUTICAL INC Quarterly Costs and Expenses in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Biomarin Pharmaceutical Inc quarterly/annual Costs and Expenses history and growth rate from Q1 2010 to Q3 2024.
  • Biomarin Pharmaceutical Inc Costs and Expenses for the quarter ending September 30, 2024 was $632M, a 14.7% increase year-over-year.
  • Biomarin Pharmaceutical Inc Costs and Expenses for the twelve months ending September 30, 2024 was $2.43B, a 11.7% increase year-over-year.
  • Biomarin Pharmaceutical Inc annual Costs and Expenses for 2023 was $2.26B, a 16.2% increase from 2022.
  • Biomarin Pharmaceutical Inc annual Costs and Expenses for 2022 was $1.95B, a 0.93% increase from 2021.
  • Biomarin Pharmaceutical Inc annual Costs and Expenses for 2021 was $1.93B, a 1.3% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $2.43B $632M +$81M +14.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $2.35B $592M +$61.9M +11.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $2.29B $560M +$26.4M +4.94% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-26
Q4 2023 $2.26B $647M +$84.6M +15% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-26
Q3 2023 $2.18B $551M +$43M +8.48% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $2.13B $530M +$35.1M +7.09% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $2.1B $534M +$152M +39.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-26
Q4 2022 $1.95B $562M +$46.3M +8.99% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-26
Q3 2022 $1.9B $508M +$45.8M +9.91% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $1.85B $495M +$4.63M +0.94% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $1.85B $382M -$78.9M -17.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-28
Q4 2021 $1.93B $516M +$12.1M +2.39% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-26
Q3 2021 $1.92B $462M -$70.8M -13.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-28
Q2 2021 $1.99B $490M +$19.6M +4.16% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $1.97B $461M +$63.8M +16.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-29
Q4 2020 $1.9B $504M +$40M +8.63% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 $1.86B $533M +$75.6M +16.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 $1.79B $470M +$41.3M +9.63% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-30
Q1 2020 $1.75B $397M -$57.6M -12.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 $1.8B $464M +$72.2M +18.5% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-25
Q3 2019 $1.73B $457M +$49.6M +12.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $1.68B $429M +$31M +7.79% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $1.65B $455M +$36.9M +8.83% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-01
Q4 2018 $1.61B $391M +$91.1M +30.3% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-26
Q3 2018 $1.52B $407M +$59.6M +17.1% Jul 1, 2018 Sep 30, 2018 10-Q/A 2019-11-04
Q2 2018 $1.46B $398M +$41.8M +11.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-02
Q1 2018 $1.42B $418M +$93.9M +29% Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
Q4 2017 $1.33B $300M -$89.5M -23% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 $1.42B $348M +$7.89M +2.32% Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-26
Q2 2017 $1.41B $356M -$517M -59.2% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-03
Q1 2017 $1.93B $324M +$6.3M +1.98% Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-27
Q4 2016 $1.92B $390M +$263M +208% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 $1.66B $340M +$49.2M +16.9% Jul 1, 2016 Sep 30, 2016 10-Q 2017-10-31
Q2 2016 $1.61B $873M +$559M +178% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-02
Q1 2016 $1.05B $318M +$48.9M +18.2% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q4 2015 $1B $127M -$162M -56.1% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-26
Q3 2015 $1.16B $291M +$125M +75.9% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 $1.04B $314M +$104M +49.3% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 $933M $269M +$90.8M +51% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-02
Q4 2014 $842M $288M +$89M +44.7% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-27
Q3 2014 $753M $165M -$22.3M -11.9% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-02
Q2 2014 $775M $211M +$53.8M +34.3% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-05
Q1 2014 $722M $178M +$17.2M +10.7% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-05
Q4 2013 $704M $199M +$20.3M +11.4% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-29
Q3 2013 $684M $188M +$49M +35.3% Jul 1, 2013 Sep 30, 2013 10-Q 2014-10-28
Q2 2013 $635M $157M +$1.89M +1.22% Apr 1, 2013 Jun 30, 2013 10-Q 2014-07-31
Q1 2013 $633M $161M +$22.3M +16.1% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-02
Q4 2012 $611M $179M +$49.6M +38.3% Oct 1, 2012 Dec 31, 2012 10-K 2015-03-02
Q3 2012 $561M $139M +$9.67M +7.5% Jul 1, 2012 Sep 30, 2012 10-Q 2013-10-28
Q2 2012 $552M $155M +$45.1M +41.1% Apr 1, 2012 Jun 30, 2012 10-Q 2013-07-29
Q1 2012 $507M $139M +$31.4M +29.3% Jan 1, 2012 Mar 31, 2012 10-Q 2013-04-29
Q4 2011 $475M $129M +$24.3M +23.2% Oct 1, 2011 Dec 31, 2011 10-K 2014-02-26
Q3 2011 $451M $129M +$29.3M +29.3% Jul 1, 2011 Sep 30, 2011 10-Q 2012-10-29
Q2 2011 $422M $110M +$21M +23.6% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-02
Q1 2011 $401M $107M +$25M +30.4% Jan 1, 2011 Mar 31, 2011 10-Q 2012-04-30
Q4 2010 $376M $105M Oct 1, 2010 Dec 31, 2010 10-K 2013-02-26
Q3 2010 $99.7M Jul 1, 2010 Sep 30, 2010 10-Q 2011-10-31
Q2 2010 $88.9M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-01
Q1 2010 $82.2M Jan 1, 2010 Mar 31, 2010 10-Q 2011-04-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.